Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

/p>

In recent months, Peregrine has implemented a number of initiatives to accelerate its three lead clinical programs.

Bavituximab Solid Tumor Clinical Program

In support of the Phase II bavituximab cancer program, Peregrine filed protocols for two breast cancer combination therapy trials and has already received regulatory approval to proceed with one of those protocols, which is assessing bavituximab in combination with docetaxel in patients with breast cancer. Patient enrollment in this trial is expected to begin in early 2008. Regulatory approval for the second breast cancer trial and for a previously filed combination therapy trial in patients with non-small cell lung cancer is expected early in 2008. The company also is taking action to accelerate its Phase I bavituximab cancer trial in the U.S., with the goal of laying the foundation for U.S. Phase II studies. Peregrine recently added a new study site in Charlotte, North Carolina, and a total of five clinical sites are now screening and recruiting patients for this study. Peregrine expects to complete the Phase I trial during 2008. The bavituximab cancer clinical program will be discussed at an important scientific forum when interim clinical data is presented in February 2008 at the 10th Annual International Symposium on Anti-Angiogenic Agents (Angio 2008).

Bavituximab Hepatitis C Virus (HCV) Clinical Program

The company's trial of bavituximab in HCV patients co-infected with HIV began enrolling and dosing patients, and with the addition of new clinical sites at The Johns Hopkins Hospital and a private clinic in Orange County, California, a total of three clinical sites are now screening and recruiting patients in this innovative study. The bavituximab HCV clinical program was awarded an oral presentation slot for the second year in a row at the prestigious Annual Meeting of the American Association for the Study of Liver Disease held last November. Final results from the Phase
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ -...d & Drug Administration (SFDA) has approved th...ts oral insulin project,(Nodlin), an innovative in...oval allows Biolaxy to initiate its first phase I ...characteristic of high blood glucose and poor,meta...
(Date:11/24/2009)... The FBI recently approved the Pr...es participating in or generating DNA records for ... Madison, WI USA (PRWEB) -- The FBI recentl...m for use by laboratories participating in, or ge...ystem (NDIS). NDIS currently contains more than se...
(Date:11/24/2009)..., TSX VENTURE: HTL , TORONTO, Nov. 24 /PRN...HTL), formerly Calotto Capital Inc., a leading pro...r the stem cell research and fertility clinic mark...lts for the third quarter ended September 30, 2009...$1.46 million compared with $1.43 million in Q3 20...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-First...A ) announced today that the company is schedule...th Care Conference on December 1, 2009 at 11:30 a....w York Palace Hotel in New York City. Jack Lief, A...cheduled to provide an overview of the company, in...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
...arents of children with,autism often grapple with ... I do something to cause the disorder? Could it be...m? Are there new medications or therapies that,mig...y 31, family members, caregivers and teachers of c... to hear from researchers on the front,line of the...
...the world converge on Regenesis, SCOTTSDALE, Ariz...echnology company that markets the Provant(R) Woun... a Scientific Advisory Board. The,Board,s purpose ...o the,mechanism of action of Provant, new product ... platform technology to clinical and industrial,ap...
...s Long-Term Growth Strategy - - First ... May 20 American Oriental,Bioengineering, Inc. (N...ical,company dedicated to improving health through...n of a broad range of prescription and over the co...he formation of a Science and,Technology Advisory ...
Other Biology Technology:First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 2First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 3Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 2Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 3American Oriental Bioengineering Forms Science and Technology Advisory Committee 2
(Date:11/25/2009)... CAWhen you eat may be just as vital to your healt...nstitute for Biological Studies. Their experiments... of thousands of genes in the liverthe body,s meta...take and not by the body,s circadian clock as conv...rmines the activity of a large number of genes com...
(Date:11/24/2009)...nce is opening new doors to understanding how soun...ring of a marine mammal or if they hear it at all...y scanners that NASA uses to detect flaws in the s...allowing scientists to peek inside the giant head ...-dimensional replicas of a whale,s hearing anatomy...
(Date:11/24/2009)...level action of a remarkable class of ring-shaped ...ith the Lawrence Berkeley National Laboratory (Ber...llography beamline at the Advanced Light Source (A...ne expression and replication, and are vital to th...ectious agents, such as the human papillomavirus, ...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3Rocket science leads to new whale discovery 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Promise for Treating Low Back Pain Radiofrequency a Trusted Technique With a New Application 49747 1Promise for Treating Low Back Pain Radiofrequency a Trusted Technique With a New Application 49747 2Judson Center Celebrates Grand Opening of its New Autism Center 49745 1Judson Center Celebrates Grand Opening of its New Autism Center 49745 2Builders Benefits and HealthEdge 28R 29 Complete Implementation of Award Winning HealthRules 28R 29 Product Suite 49743 1Builders Benefits and HealthEdge 28R 29 Complete Implementation of Award Winning HealthRules 28R 29 Product Suite 49743 2
...ch fructose and glucose can turn off the gene that...strogen in the body, shows a new study in mice and... the Journal of Clinical Investigation. This disco...x carbohydrates and avoid sugar. Table sugar is ma... commonly used in sweetened beverages, syrups, and...
...t a better plant, one that produces more leaves an...archers accomplished the feat using a computer mod... the first model to simulate every step of the pho...ar in the October issue of Plant Physiology, and w...ence in Bangkok, Thailand. The research was sponso...
...y at Rutgers New Jersey Experiment Station (NJAES)...greement aimed at using integrated pest management...uito (Aedes albopictus) across the country. The $3...ricultural Research Service as one of its area-wid... tiger mosquito into the U.S. was one of the most ...
Other Biology News:Too much sugar turns off gene that controls the effects of sex steroids 2Researchers successfully simulate photosynthesis and design a better leaf 2Researchers successfully simulate photosynthesis and design a better leaf 3USDA Cooperative Agreement funds mosquito project at Rutgers 2USDA Cooperative Agreement funds mosquito project at Rutgers 3
Mouse Anti-ROCK-1 (cleaved) Monoclonal Antibody, Unconjugated from BioVision
Rabbit Anti-Cullin-1 Polyclonal Antibody, Unconjugated from AnaSpec
Feline IL-2 ELISpot Kit from R&D Systems
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids* from Molecular Probes (Invitrogen)
Biology Products: